Skip to main content

Oruka Therapeutics, Inc.

ORKA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000907654

In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.

Q4 2023 vs. Q3 2023

How the institutions holding Oruka Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of ORKA: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders2125+4
Shares3.26M7.48M+4.22M (+129.5%)
Value$6.55M$12.7M+$6.16M (+94.1%)

New holders (5)

Institutions that held Oruka Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to ORKA in Q4 2023
InstitutionSharesValue% of portfolio
Cable Car Capital LLC4,000,452$6.80M7.12%
Standard Life Aberdeen plc32,461$55.2K0.00%
Two Sigma Securities, LLC12,119$20.6K0.00%
Citadel Advisors LLC6,320$10.7K0.00%
Simplex Trading, LLC100$00.00%

Sold out (1)

Institutions that held Oruka Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of ORKA in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Bridgeway Capital Management, LLC46,948$94.4K